(BioNTech) BioNTech SE has treated the first colorectal cancer patient using the individualized vaccine BNT122 in a phase 2 trial.
BioNTech has already initiated trials in the US, Spain, Germany, and Belgium and seeks to enroll 200 patients in testing the BNT122 efficacy.
The company will seek a joint development of BNT122 with Genentech, a Roche Group member, in other trials.
BioNTech co-founder and chief medical officer Özlem Türeci says the clinical trials aim to single out high-risk patients and evaluate whether the individualized mRNA vaccine can prevent relapses in colorectal cancer treatment.
Colorectal cancer is viewed as the second deadliest, calling for novel therapies in its treatment.
BNTX: NASDAQ is down -13.61%.
